美多芭联合普拉克索治疗帕金森病的临床疗效及对患者生命质量的影响  

Clinical efficacy of Metoba combined with pramipexole in the treatment of Parkinson's disease and its influence on patients'quality of life

作　　者：孙红 SUN Hong(Department of Neurology,Central Hospital of China Railway 19 Bureau Group Co.,LTD.,Liaoyang,Liaoning,111000,China)

机构地区：[1]中铁十九局集团有限公司中心医院神经内科,辽宁辽阳111000

出　　处：《当代医学》2023年第22期98-101,共4页Contemporary Medicine

基　　金：辽宁省自然科学基金(2018011151)。

摘　　要：目的观察美多芭联合普拉克索治疗帕金森病的临床疗效及对患者生命质量的影响。方法选取2018年4月至2020年7月于本院进行治疗的62例帕金森病患者作为研究对象,按照入院时间分为对照组(2018年4月至2019年5月)与观察组(2019年6月至2020年7月),各31例。对照组单行美多芭治疗,观察组在对照组治疗基础上联合普拉克索治疗,比较两组治疗前后帕金森氏病综合评分量表(UPDRS)评分、简易智能精神状态检查量表(MMSE)评分、蒙特利尔认知评估量表(MoCA)评分、帕金森病患者生活质量量表-39项(PDQ-39)评分。结果治疗3个月后,两组UPDRS分值均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。治疗3个月后,两组MMSE、MoCA评分均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05)。治疗3个月后,两组PDQ-39评分均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。结论美多芭联合普拉克索治疗帕金森病效果显著,可显著改善患者认知功能,有效提升其生命质量,值得临床推广应用。Objective To observe the clinical efficacy of Metoba combined with pramipexole in the treatment of Parkinson's disease and its in-fluence on patients'quality of life.Methods A total of 62 patients with Parkinson's disease who were treated in our hospital from April 2018 to July 2020 were selected as the study subjects,and they were divided into the control group(April 2018 to May 2019)and the observation group(June 2019 to July 2020)according to the admission time,with 31 cases in each group.The control group was treated with metoba alone,and the observa-tion group was treated with pramipexole on the basis of the control group.The unified Parkinson's disease rating scale(UPDRS),mini-mental state examination(MMSE),Montreal cognitive assessment scale(MoCA)and Parkinson's disease questionnaire-39(PDQ-39)scores before and after treat-ment were compared between the two groups.Results After 3 months of treatment,UPDRS scores of two groups were lower than before treatment,and observation group was lower than the control group,the difference was statistically significant(P<0.05).After 3 months of treatment,MMSE and MoCA scores of two groups were higher than before treatment,and the observation group was higher than the control group,the difference was statisti-cally significant(P<0.05).After 3 months of treatment,PDQ-39 scores of two groups were lower than before treatment,and the observation group was lower than the control group,the difference was statistically significant(P<0.05).Conclusion Metoba combined with pramipexole can signifi-cantly improve the cognitive function and quality of life of patients with Parkinson's disease,which is worthy of clinical promotion and application.

关 键 词：美多芭 普拉克索 帕金森病 帕金森氏病综合评分量表 帕金森病患者生活质量量表 

分 类 号：R742.5[医药卫生—神经病学与精神病学]